American Century Companies Inc. lowered its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 3.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 6,297,503 shares of the company’s stock after selling 205,160 shares during the quarter. American Century Companies Inc. owned 0.23% of Merck & worth $403,607,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRK. Perennial Advisors LLC increased its position in shares of Merck & by 10.7% during the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after purchasing an additional 157 shares during the last quarter. Stelac Advisory Services LLC bought a new position in shares of Merck & during the 2nd quarter valued at approximately $104,000. Vigilant Capital Management LLC increased its position in shares of Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after purchasing an additional 250 shares during the last quarter. Cascade Investment Advisors Inc. increased its position in shares of Merck & by 15.5% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after purchasing an additional 232 shares during the last quarter. Finally, Solaris Asset Management LLC grew its position in Merck & by 6.3% in the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after acquiring an additional 115 shares during the last quarter. 73.15% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Thomas H. Glocer sold 5,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total transaction of $281,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.25% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “American Century Companies Inc. Has $403.61 Million Stake in Merck & Company, Inc. (MRK)” was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://transcriptdaily.com/2017/11/15/american-century-companies-inc-has-403-61-million-stake-in-merck-company-inc-mrk.html.
Several brokerages have commented on MRK. Cowen and Company reaffirmed a “hold” rating and issued a $70.00 price objective on shares of Merck & in a research report on Friday, November 3rd. Berenberg Bank reaffirmed a “hold” rating on shares of Merck & in a research report on Wednesday, November 1st. Jefferies Group LLC downgraded Merck & from a “hold” rating to an “underperform” rating in a research report on Wednesday, November 1st. BMO Capital Markets set a $68.00 price objective on Merck & and gave the company a “buy” rating in a research report on Monday, October 30th. Finally, Leerink Swann cut their price objective on Merck & from $70.00 to $69.00 and set a “market perform” rating on the stock in a research report on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $67.07.
Shares of Merck & Company, Inc. (MRK) opened at $54.99 on Wednesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.16 and a current ratio of 1.43. The firm has a market capitalization of $150,116.47, a price-to-earnings ratio of 14.16, a P/E/G ratio of 2.37 and a beta of 0.78. Merck & Company, Inc. has a 12 month low of $54.41 and a 12 month high of $66.80.
Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. The firm had revenue of $10.33 billion during the quarter, compared to analysts’ expectations of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.07 EPS. analysts anticipate that Merck & Company, Inc. will post 3.95 earnings per share for the current fiscal year.
Merck & Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.